Filing Flows

Filing Flows › RenovoRx (RNXT) › Next earnings date

RenovoRx (RNXT) earnings: missed the estimate

RenovoRx (RNXT) reported on Nov 5, 2026 and missed the EPS estimate: −$0.07 against −$0.05 (-40.0%). Revenue was $1.1M for Q3 2026, +301% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−40.0% vs estimate
Beat rate20%

The last report

RenovoRx reported revenue of $1.1M for the third quarter 2026 (+301% Y/Y), net loss $3.6M. How it makes money → · Every quarter →

RenovoRx: EPS against the estimate, last 5 reportsRenovoRx: EPS against the estimate, last 5 reportsEstimateReported−$0.08−$0.08Nov 25−$0.08−$0.08Mar 26−$0.08−$0.08May 26−$0.07−$0.05Aug 26−$0.05−$0.07Nov 26
Latest (Nov 26): Estimate −$0.05, Reported −$0.07.

RenovoRx's latest quarter

RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did RenovoRx beat earnings?

RenovoRx (RNXT) reported on Nov 5, 2026 and missed the EPS estimate: −$0.07 against −$0.05 (-40.0%).

When does RNXT report earnings?

The next date is not set yet.

Does RenovoRx usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.